These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

143 related articles for article (PubMed ID: 21209853)

  • 61. Flaxseed oil enhances the effectiveness of trastuzumab in reducing the growth of HER2-overexpressing human breast tumors (BT-474).
    Mason JK; Fu M; Chen J; Thompson LU
    J Nutr Biochem; 2015 Jan; 26(1):16-23. PubMed ID: 25441844
    [TBL] [Abstract][Full Text] [Related]  

  • 62. The actin modulator hMENA regulates GAS6-AXL axis and pro-tumor cancer/stromal cell cooperation.
    Melchionna R; Spada S; Di Modugno F; D'Andrea D; Di Carlo A; Panetta M; Mileo AM; Sperduti I; Antoniani B; Gallo E; Lawlor RT; Piemonti L; Visca P; Milella M; Grazi GL; Facciolo F; Chen E; Scarpa A; Nisticò P
    EMBO Rep; 2020 Nov; 21(11):e50078. PubMed ID: 32909687
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Prognostic value of HER3, PTEN and p-HER2 expression in patients with HER2positive breast cancer.
    Dębska-Szmich S; Kusińska R; Czernek U; Szydłowska-Pazera K; Habib-Lisik M; Piekarski JH; Olas E; Kulig A; Ułańska M; Kalinka-Warzocha E; Potemski P
    Postepy Hig Med Dosw (Online); 2015 May; 69():586-97. PubMed ID: 25983297
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Anti-cancer effect of metformin by suppressing signaling pathway of HER2 and HER3 in tamoxifen-resistant breast cancer cells.
    Kim J; Lee J; Kim C; Choi J; Kim A
    Tumour Biol; 2016 May; 37(5):5811-9. PubMed ID: 26581908
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Evaluation of the prognostic value of all four HER family receptors in patients with metastatic breast cancer treated with trastuzumab: A Hellenic Cooperative Oncology Group (HeCOG) study.
    Koutras A; Lazaridis G; Koliou GA; Kouvatseas G; Christodoulou C; Pectasides D; Kotoula V; Batistatou A; Bobos M; Tsolaki E; Papadopoulou K; Pentheroudakis G; Papakostas P; Pervana S; Petraki K; Chrisafi S; Razis E; Psyrri A; Bafaloukos D; Kalogeras KT; Kalofonos HP; Fountzilas G
    PLoS One; 2018; 13(12):e0207707. PubMed ID: 30521571
    [TBL] [Abstract][Full Text] [Related]  

  • 66. The effects of bufadienolides on HER2 overexpressing breast cancer cells.
    Wang T; Mu L; Jin H; Zhang P; Wang Y; Ma X; Pan J; Miao J; Yuan Y
    Tumour Biol; 2016 Jun; 37(6):7155-63. PubMed ID: 26662961
    [TBL] [Abstract][Full Text] [Related]  

  • 67. A new model system identifies epidermal growth factor receptor-human epidermal growth factor receptor 2 (HER2) and HER2-human epidermal growth factor receptor 3 heterodimers as potent inducers of oesophageal epithelial cell invasion.
    Fichter CD; Przypadlo CM; Buck A; Herbener N; Riedel B; Schäfer L; Nakagawa H; Walch A; Reinheckel T; Werner M; Lassmann S
    J Pathol; 2017 Dec; 243(4):481-495. PubMed ID: 28940194
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Down-regulation of programmed cell death 4 (PDCD4) is associated with aromatase inhibitor resistance and a poor prognosis in estrogen receptor-positive breast cancer.
    Chen Z; Yuan YC; Wang Y; Liu Z; Chan HJ; Chen S
    Breast Cancer Res Treat; 2015 Jul; 152(1):29-39. PubMed ID: 26026468
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Modulation of HER2 expression by ferulic acid on human breast cancer MCF7 cells.
    Chang CJ; Chiu JH; Tseng LM; Chang CH; Chien TM; Wu CW; Lui WY
    Eur J Clin Invest; 2006 Aug; 36(8):588-96. PubMed ID: 16893382
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Rictor/mTORC2 Drives Progression and Therapeutic Resistance of HER2-Amplified Breast Cancers.
    Morrison Joly M; Hicks DJ; Jones B; Sanchez V; Estrada MV; Young C; Williams M; Rexer BN; Sarbassov dos D; Muller WJ; Brantley-Sieders D; Cook RS
    Cancer Res; 2016 Aug; 76(16):4752-64. PubMed ID: 27197158
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Cytosolic phospholipase A2 activation correlates with HER2 overexpression and mediates estrogen-dependent breast cancer cell growth.
    Caiazza F; Harvey BJ; Thomas W
    Mol Endocrinol; 2010 May; 24(5):953-68. PubMed ID: 20211985
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Prolyl isomerase Pin1 is highly expressed in Her2-positive breast cancer and regulates erbB2 protein stability.
    Lam PB; Burga LN; Wu BP; Hofstatter EW; Lu KP; Wulf GM
    Mol Cancer; 2008 Dec; 7():91. PubMed ID: 19077306
    [TBL] [Abstract][Full Text] [Related]  

  • 73. HER3 status by immunohistochemistry is correlated with poor prognosis in hormone receptor-negative breast cancer patients.
    Bae SY; La Choi Y; Kim S; Kim M; Kim J; Jung SP; Choi MY; Lee SK; Kil WH; Lee JE; Nam SJ
    Breast Cancer Res Treat; 2013 Jun; 139(3):741-50. PubMed ID: 23722313
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Ki67 index, HER2 status, and prognosis of patients with luminal B breast cancer.
    Cheang MC; Chia SK; Voduc D; Gao D; Leung S; Snider J; Watson M; Davies S; Bernard PS; Parker JS; Perou CM; Ellis MJ; Nielsen TO
    J Natl Cancer Inst; 2009 May; 101(10):736-50. PubMed ID: 19436038
    [TBL] [Abstract][Full Text] [Related]  

  • 75. HER2 Amplification in Tumors Activates PI3K/Akt Signaling Independent of HER3.
    Ruiz-Saenz A; Dreyer C; Campbell MR; Steri V; Gulizia N; Moasser MM
    Cancer Res; 2018 Jul; 78(13):3645-3658. PubMed ID: 29760043
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Characterization of Expression and Function of the Formins FHOD1, INF2, and DAAM1 in HER2-Positive Breast Cancer.
    Peippo M; Gardberg M; Kronqvist P; Carpén O; Heuser VD
    J Breast Cancer; 2023 Dec; 26(6):525-543. PubMed ID: 37985384
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Quantitative assessment of invasive mena isoforms (Menacalc) as an independent prognostic marker in breast cancer.
    Agarwal S; Gertler FB; Balsamo M; Condeelis JS; Camp RL; Xue X; Lin J; Rohan TE; Rimm DL
    Breast Cancer Res; 2012 Sep; 14(5):R124. PubMed ID: 22971274
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Expression and Distribution Characteristics of Human Ortholog of Mammalian Enabled (hMena) in Glioma.
    Dong XT; Yang XJ; Wang HM; Wang W; Yu L; Zhang B; Yu SP; Ming HL
    Chin J Cancer Res; 2011 Dec; 23(4):312-6. PubMed ID: 23359755
    [TBL] [Abstract][Full Text] [Related]  

  • 79. hMENA(11a) contributes to HER3-mediated resistance to PI3K inhibitors in HER2-overexpressing breast cancer cells.
    Trono P; Di Modugno F; Circo R; Spada S; Di Benedetto A; Melchionna R; Palermo B; Matteoni S; Soddu S; Mottolese M; De Maria R; Nisticò P
    Oncogene; 2016 Feb; 35(7):887-96. PubMed ID: 25961924
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Splicing program of human MENA produces a previously undescribed isoform associated with invasive, mesenchymal-like breast tumors.
    Di Modugno F; Iapicca P; Boudreau A; Mottolese M; Terrenato I; Perracchio L; Carstens RP; Santoni A; Bissell MJ; Nisticò P
    Proc Natl Acad Sci U S A; 2012 Nov; 109(47):19280-5. PubMed ID: 23129656
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.